PriceTargets.com logo

Elekta AB (publ) - EKTAY Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.86 As of 04/26/2024 01:00 AM ET
▲ +0.16 (2.39%)

This chart shows the closing price for EKTAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elekta AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EKTAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EKTAY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Elekta AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.86.

This chart shows the closing price for EKTAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 2 polled investment analysts is to sell stock in Elekta AB (publ). This Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/5/2023BarclaysInitiated CoverageUnderweight
7/12/2023The Goldman Sachs GroupInitiated CoverageSell
3/7/2023Sanford C. BernsteinInitiated CoverageOutperform
2/14/2023AlphaValueUpgradeBuy
1/31/2023Nordea Equity ResearchUpgradeHold ➝ Buy
1/12/2023Morgan StanleyLower TargetUnderweight ➝ UnderweightSEK 63 ➝ SEK 62
12/12/2022CitigroupInitiated CoverageSell
10/18/2022Morgan StanleyInitiated CoverageUnderweight
4/26/2022JPMorgan Chase & Co.Lower TargetUnderweight ➝ UnderweightSEK 79 ➝ SEK 69
2/25/2022JPMorgan Chase & Co.Lower TargetSEK 87 ➝ SEK 79
2/15/2022DanskeDowngradeBuy ➝ Hold
1/20/2022Jefferies Financial GroupInitiated CoverageUnderperform
8/27/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
6/2/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
4/27/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
3/18/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
1/20/2021Berenberg BankReiterated RatingBuy
1/7/2021Northland SecuritiesInitiated CoverageOutperform
12/9/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight
11/27/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/26/2020JPMorgan Chase & Co.Reiterated RatingNeutral
9/9/2020Morgan StanleyReiterated RatingEqual Weight
9/3/2020Berenberg BankReiterated RatingBuy
8/27/2020JPMorgan Chase & Co.Reiterated RatingNeutral
8/3/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
7/29/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight
6/1/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
5/7/2020UBS GroupDowngradeBuy ➝ Neutral
4/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
2/21/2020Pareto SecuritiesDowngradeBuy ➝ Hold
7/16/2019Jefferies Financial GroupUpgradeUnderperform ➝ Hold
(Data available from 4/26/2019 forward)

News Sentiment Rating

1.94 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Elekta AB (publ) logo
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Read More

Today's Range

Now: $6.86
Low: $6.79
High: $6.87

50 Day Range

MA: $7.34
Low: $6.70
High: $7.82

52 Week Range

Now: $6.86
Low: $6.52
High: $8.65

Volume

32,189 shs

Average Volume

8,486 shs

Market Capitalization

$2.63 billion

P/E Ratio

19.04

Dividend Yield

2.30%

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Elekta AB (publ)?

The following equities research analysts have issued stock ratings on Elekta AB (publ) in the last twelve months: Barclays PLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for EKTAY.

What is the current price target for Elekta AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Elekta AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Elekta AB (publ) in the next year.
View the latest price targets for EKTAY.

What is the current consensus analyst rating for Elekta AB (publ)?

Elekta AB (publ) currently has 2 sell ratings from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe EKTAY will underperform the market and that investors should sell shares of Elekta AB (publ).
View the latest ratings for EKTAY.

What other companies compete with Elekta AB (publ)?

Other companies that are similar to Elekta AB (publ) include RadNet, Guardant Health, Fortrea, Veracyte and Viridian Therapeutics. Learn More about companies similar to Elekta AB (publ).

How do I contact Elekta AB (publ)'s investor relations team?

Elekta AB (publ)'s physical mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company's listed phone number is (685) 872-5400 and its investor relations email address is [email protected]. The official website for Elekta AB (publ) is www.elekta.com. Learn More about contacing Elekta AB (publ) investor relations.